Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cell Death Suppression Increases Efficacy of M2 Vaccines

16.01.2008
Significant public attention has recently been focused on the development of new anti-influenza (flu) vaccines that provide protection against a broad spectrum of viral strains. One proposed strategy is to utilize conserved viral protein, M2. Clinical trials of M2-containing influenza vaccines were recently initiated by US and European companies.

Scientists from Cure Lab, Inc. in collaboration with Boston University School of Medicine published new findings indicating that unmodified M2 may have a negative effect on anti-influenza vaccination. The researchers also demonstrated how this detrimental effect of M2 can be eliminated, thereby allowing any future M2-containing vaccine to be both broadly protective as well as safe. This study appears in the January 16th issue of the online journal PLoS ONE, which provides free access of its publications to scientists and the general public.

Annual vaccinations against seasonal flu are known to be insufficient to fully prevent disease. The cause of this is a single predicament: current vaccines predominantly target two viral surface proteins, hemaglutinin and neuraminidase that are constantly mutating. Thus, a particular vaccine can be protective against a viral strain carrying matching hemaglutinin and neuraminidase, but will lose efficacy as soon as these proteins change (gradually or even in a single step). The latter process is known to continuously occur in nature.

In their attempts to make current strain-specific vaccines effective, the World Health Organization (WHO) has to annually predict the most likely viral strains that will be responsible for the next seasonal flu outbreak. This process takes place just a few months before flu season starts. This process is error prone, that is, it is possible that the vaccine may be manufactured against non-matching viral strains and not the one that may actually cause the epidemic. Moreover, as long as vaccines remain to be strain specific, it will be impossible to both manufacture them in advance and to enable their stockpiling. This, in turn, drives up the vaccine cost and makes its efficient world-wide distribution almost impossible.

Finally, the new strains of flu virus usually emerge in Asia and then migrate to Europe and North America. Recently, Indonesia demonstrated its reluctance to cooperate with WHO and restricted information exchange regarding the nature of a novel influenza strain. Several other countries in the region were sympathetic to Indonesia’s actions. These and many other problems will never be fully resolved until anti-flu vaccines cease to be strain-specific.

However, all of the problems mentioned above could be alleviated by the development of a new generation of vaccine. Such a vaccine should be based on conserved flu proteins, which to a significant degree remain constant among all flu strains.

In addition to continuously mutating proteins, flu virus also possesses nucleoprotein (NP), and major matrix protein (M1), that reside inside the viral particle, and do not generate a strong antibody response. This may be the reason why these proteins do not naturally undergo significant mutagenesis and posses a striking degree of similarity among all influenza strains. Another conserved flu protein that is strongly expressed in virus-infected cells is a nonstructural protein 1 (NS1).

In the March issue of the scientific journal “Influenza and Other Respiratory Viruses”, Massachusetts-based biotech company Cure Lab, Inc. reported that vaccinating mice with a combination of genes encoding these three conserved proteins of flu virus, NP, M1 and NS1, protected mice against human as well as avian strains of flu virus. In particular, this included an experiment demonstrating protection against bird flu virus that encodes type 5 hemaglutinin or H5. The challenge with this viral strain was used as a model of potential pandemic outbreak, which many believe may be caused by spreading of avian H5N1 virus to the human population. Moreover, in the same paper, Cure Lab reported that the same combination of three conserved viral genes provided significant protection against H5-carrying influenza strain in the chicken model.

In addition to Cure Lab, several other companies are also pursuing attempts to utilize genes encoding conserved flu proteins as vaccine components. This includes the California-based company Vical, known for its chemical adjuvant Vaxfectin. Vical included another extremely conserved flu protein, M2 into its proposed anti-flu product. M2 is present in low copy numbers at the surface of influenza viral particles, but is expressed abundantly on the surface of infected cells. Most of the research groups, including British biotech company, Acambis, have attempted to utilize only an extracellular domain of M2 protein called M2e. Despite some encouraging results demonstrating that if used at very high doses, M2e may induce a protective antibody response, the current opinion in the field is that it should be used only as a supplement to more potent antigens. One of the reasons may be that M2e lacks possible protective epitopes located within the intracellular and trans-membrane parts of M2. In addition, at least one recent report demonstrated that vaccination with M2e-encoding gene used in combination with the NP gene, exacerbated disease and increased mortality in pigs. In contrast to the Acambis strategy, Vical has included the gene encoding a full-size M2 into its vaccine prototype. The company reported that it had initiated clinical trials already.

“As it often happens, path-finding research starts as a result of an unexpected failure,” said Dr. Alex Shneider, the senior author on the PLoS ONE paper and Cure Lab’s CEO. “Initially, we believed that simply adding a gene encoding the full size M2 to our previously developed vaccine prototype would further increase the protective properties of the vaccine. Instead, we observed exactly the opposite”.

Puzzled with such a counterintuitive result, Cure Lab went from product development to a basic science approach and asked the question: “Why would M2 decrease the efficiency of influenza vaccination?” Interestingly, for a number of years M2 was known to be insufficiently immunogenic in vaccine studies, which in fact, necessitated the utilization either of high doses of M2 or the shift to M2e-peptide as mentioned above. Earlier, Cure Lab demonstrated that M2 on its own may kill the cells producing this protein (uninfected with influenza). The scientists hypothesized that this is the underlying reason for the undesirable effect of M2 on vaccination. If this assumption was correct, then it would immediately suggest how to resolve the problem.

In order for M2 not to be able to exercise its negative functions, the protein should be “trapped” or neutralized in such a manner that prevents it from cell killing. Therefore, Cure Lab fused M2 with other proteins constituting a vaccine in such a way that NP, M1 and NS1 proteins restrict M2 functionality. This specific composite poly-protein, which did not kill the host cells, was selected based on its biochemical properties and cell-based assays.

Further animal testing demonstrated that the fusion construct containing all four conserved influenza proteins including “neutralized” M2, possesses much more promising protective properties than the same poly-protein without M2. “It shows us that the M2-gene can indeed be a valuable component of a novel anti-influenza vaccine if its negative effect is eliminated. One such approach is delineated in the PLoS ONE publication. Other possibilities are prevention of M2-induced cell death by introduction of specific mutations into the M2 gene or combining vaccination with drugs targeting M2, for example, amantadine”- said Dr. Alex Shneider.

“Our data does not necessarily indicate that clinical trials of vaccines utilizing genes encoding a full-size influenza M2 protein is unsafe” – stated Dr. Petr Ilyinskii, Principal Scientist at Cure Lab. “At the same time, it may suggest that the efficacy of M2-containing vaccines is not optimal for clinical trials and medical applications”.

Meanwhile, pandemic flu continues to be one of the major threats to society. It remains to be seen whether it will be eliminated through the development of novel vaccines similarly to smallpox and polio or, at least, becomes controllable.

Andrew Hyde | alfa
Further information:
http://www.plosone.org/doi/pone.0001417

More articles from Health and Medicine:

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Scientist invents way to trigger artificial photosynthesis to clean air

26.04.2017 | Materials Sciences

Ammonium nitrogen input increases the synthesis of anticarcinogenic compounds in broccoli

26.04.2017 | Agricultural and Forestry Science

SwRI-led team discovers lull in Mars' giant impact history

26.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>